Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies

Figure 5

Cross-sectional analysis of blood lymphocyte counts stratified by treatment (GAD65-alum (Diamyd)/placebo) presented as boxplots at study follow-up visits 0, 1, 2, 4, 6, 8, and 10. Lymphocyte counts were lower in the GAD65-alum-treated group compared to placebo at visits 8 and 10. The estimates, 95% confidence intervals, and values for those visits are provided in the figure, and complete results are presented in the Supplementary Table 1.